50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,666.98 (-1.40%)
DOW   29,363.40 (-1.08%)
QQQ   276.30 (-1.30%)
AAPL   146.75 (-2.06%)
MSFT   239.11 (-0.81%)
META   139.36 (-1.59%)
GOOGL   98.89 (-1.16%)
AMZN   116.25 (-1.49%)
TSLA   282.80 (-1.74%)
NVDA   124.29 (-2.41%)
NIO   16.94 (-2.25%)
BABA   78.75 (-2.77%)
AMD   67.35 (-1.48%)
T   15.74 (-0.57%)
MU   50.08 (-1.80%)
CGC   2.95 (-2.96%)
F   11.98 (-1.64%)
GE   64.18 (-0.43%)
DIS   98.10 (-1.31%)
AMC   7.48 (-2.48%)
PYPL   89.39 (-1.90%)
PFE   44.35 (-0.18%)
NFLX   242.16 (-1.24%)
S&P 500   3,666.98 (-1.40%)
DOW   29,363.40 (-1.08%)
QQQ   276.30 (-1.30%)
AAPL   146.75 (-2.06%)
MSFT   239.11 (-0.81%)
META   139.36 (-1.59%)
GOOGL   98.89 (-1.16%)
AMZN   116.25 (-1.49%)
TSLA   282.80 (-1.74%)
NVDA   124.29 (-2.41%)
NIO   16.94 (-2.25%)
BABA   78.75 (-2.77%)
AMD   67.35 (-1.48%)
T   15.74 (-0.57%)
MU   50.08 (-1.80%)
CGC   2.95 (-2.96%)
F   11.98 (-1.64%)
GE   64.18 (-0.43%)
DIS   98.10 (-1.31%)
AMC   7.48 (-2.48%)
PYPL   89.39 (-1.90%)
PFE   44.35 (-0.18%)
NFLX   242.16 (-1.24%)
S&P 500   3,666.98 (-1.40%)
DOW   29,363.40 (-1.08%)
QQQ   276.30 (-1.30%)
AAPL   146.75 (-2.06%)
MSFT   239.11 (-0.81%)
META   139.36 (-1.59%)
GOOGL   98.89 (-1.16%)
AMZN   116.25 (-1.49%)
TSLA   282.80 (-1.74%)
NVDA   124.29 (-2.41%)
NIO   16.94 (-2.25%)
BABA   78.75 (-2.77%)
AMD   67.35 (-1.48%)
T   15.74 (-0.57%)
MU   50.08 (-1.80%)
CGC   2.95 (-2.96%)
F   11.98 (-1.64%)
GE   64.18 (-0.43%)
DIS   98.10 (-1.31%)
AMC   7.48 (-2.48%)
PYPL   89.39 (-1.90%)
PFE   44.35 (-0.18%)
NFLX   242.16 (-1.24%)
S&P 500   3,666.98 (-1.40%)
DOW   29,363.40 (-1.08%)
QQQ   276.30 (-1.30%)
AAPL   146.75 (-2.06%)
MSFT   239.11 (-0.81%)
META   139.36 (-1.59%)
GOOGL   98.89 (-1.16%)
AMZN   116.25 (-1.49%)
TSLA   282.80 (-1.74%)
NVDA   124.29 (-2.41%)
NIO   16.94 (-2.25%)
BABA   78.75 (-2.77%)
AMD   67.35 (-1.48%)
T   15.74 (-0.57%)
MU   50.08 (-1.80%)
CGC   2.95 (-2.96%)
F   11.98 (-1.64%)
GE   64.18 (-0.43%)
DIS   98.10 (-1.31%)
AMC   7.48 (-2.48%)
PYPL   89.39 (-1.90%)
PFE   44.35 (-0.18%)
NFLX   242.16 (-1.24%)
NASDAQ:UBX

Unity Biotechnology - UBX Stock Forecast, Price & News

$0.43
+0.02 (+4.91%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.40
$0.43
50-Day Range
$0.40
$1.37
52-Week Range
$0.39
$3.64
Volume
891,348 shs
Average Volume
1.49 million shs
Market Capitalization
$29.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.20

Unity Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,584.6% Upside
$7.20 Price Target
Short Interest
Healthy
2.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
-0.01mentions of Unity Biotechnology in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$18,821 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.72) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

225th out of 1,096 stocks

Pharmaceutical Preparations Industry

97th out of 548 stocks

UBX stock logo

About Unity Biotechnology (NASDAQ:UBX) Stock

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

UNITY Biotechnology Inc
Why Is Unity Biotechnology (UBX) Stock Up 71% Today?
See More Headlines
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Company Calendar

Last Earnings
8/12/2022
Today
9/29/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.20
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,584.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-60,720,000.00
Pretax Margin
-1,179.18%

Debt

Sales & Book Value

Annual Sales
$4.78 million
Book Value
$1.03 per share

Miscellaneous

Free Float
67,144,000
Market Cap
$29.77 million
Optionable
Not Optionable
Beta
0.73

Key Executives

  • Dr. Anirvan Ghosh Ph.D. (Age 58)
    CEO & Director
    Comp: $885.54k
  • Dr. Nathaniel E. David A.B. (Age 54)
    Ph.D., Co-Founder & Exec. Director
    Comp: $40k
  • Ms. Lynne Marie Sullivan (Age 55)
    CFO & Head of Corp. Devel.
    Comp: $614.84k
  • Dr. Jamie Dananberg M.D. (Age 64)
    Chief Medical Officer
    Comp: $635.79k
  • Dr. Jan M. van Deursen
    Founder
  • Dr. Judith Campisi Ph.D.
    Founder
  • Mr. Daohong Zhou M.D.
    Founder
  • Mr. Nathan Guz Ph.D.
    VP of Operations
  • Mr. Alexander Azoy (Age 46)
    VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer
  • Dr. Przemyslaw Sapieha Ph.D.
    Chief Scientific Advisor













UBX Stock - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UBX shares.
View UBX analyst ratings
or view top-rated stocks.

What is Unity Biotechnology's stock price forecast for 2022?

6 Wall Street analysts have issued 12-month price targets for Unity Biotechnology's stock. Their UBX share price forecasts range from $4.00 to $12.00. On average, they expect the company's share price to reach $7.20 in the next twelve months. This suggests a possible upside of 1,584.6% from the stock's current price.
View analysts price targets for UBX
or view top-rated stocks among Wall Street analysts.

How have UBX shares performed in 2022?

Unity Biotechnology's stock was trading at $1.46 on January 1st, 2022. Since then, UBX stock has decreased by 70.7% and is now trading at $0.4274.
View the best growth stocks for 2022 here
.

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our UBX earnings forecast
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.09. The firm had revenue of $0.24 million for the quarter.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.38%), FMR LLC (1.35%), Millennium Management LLC (0.48%), State Street Corp (0.19%), Franklin Resources Inc. (0.09%) and Virtu Financial LLC (0.09%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends
.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $0.43.

How much money does Unity Biotechnology make?

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $29.77 million and generates $4.78 million in revenue each year. The company earns $-60,720,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How can I contact Unity Biotechnology?

The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.

This page (NASDAQ:UBX) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.